The Native Antigen Company human coronavirus antigens and antibodies

Thursday, 12 May, 2022 | Supplied by: BioNovus Life Sciences

The Native Antigen Company develops and manufactures high-quality recombinant antigens and antibodies as well as offering a range of services for the diagnostic and biopharmaceutical industries. The company’s VirtuE mammalian expression system has been developed for the purpose of producing native-like proteins, which are being widely adopted by in vitro diagnostic, vaccine and academic groups in cutting-edge R&D, where correct folding and glycosylation are vital.

There are six different coronaviruses that can infect humans and cause illness. These comprise the four common coronaviruses — 229E and NL63 (alpha coronaviruses), and OC43 and HKU1 (beta coronaviruses) — and two other coronaviruses, MERS-CoV and SARS-CoV, both of which can cause severe illness and remain a significant public health concern. Following the declaration of SARS-CoV-2 pandemic by the WHO in March 2020, Native Antigen has rapidly expanded its range of SARS-CoV-2 recombinant antigens and antibodies.

To support the investigation of SARS-CoV-2 variants, the company offers a growing range of mutant Spike antigens. Expressed through the VirtuE mammalian expression system, the antigens display full glycosylation and proper folding for use in the development of high-performance assays and other applications.

Phone: 02 9484 0931
Related Products

TdB Labs dextran sulfate sodium (DSS) for colitis

DSS for colitis is supplied as the sodium salt and is stabilised by a small addition of phosphate...

Merck ReadyStream media preparation system

Merck's Life Science business sector has launched the innovative ReadyStream system — a...

Merck ZooMAb recombinant antibodies

ZooMAb antibodies use recombinant technology, which offers an endless and consistent supply while...

  • All content Copyright © 2022 Westwick-Farrow Pty Ltd